Today: 9 June 2026
IBM stock price jumps before the bell after earnings beat — what traders are watching next
29 January 2026
2 mins read

IBM stock price jumps before the bell after earnings beat — what traders are watching next

New York, Jan 29, 2026, 04:56 EST — Premarket

  • IBM shares jumped roughly 8% in premarket trading following quarterly results that beat expectations
  • IBM expects constant-currency revenue growth to exceed 5% in 2026, along with an increase in free cash flow
  • Investors are focused on Red Hat’s growth cooling off and IBM’s decision to stop reporting its “AI book of business” metric separately

Shares of International Business Machines (IBM) surged in premarket action Thursday, climbing 7.86% to $317.27 by 5:00 a.m. EST. The stock had closed Wednesday at $294.16.

Investors are sorting through a packed earnings slate and a calmer rates environment after the Federal Reserve held steady on policy. Tech stocks have shown mixed responses, with strong earnings quickly attracting buying pressure in late and early trading sessions.

IBM’s latest results land amid a tough debate over whether AI investments are driving steady revenue or just hype. The company topped fourth-quarter revenue and profit forecasts, reporting its “AI book of business” climbed to $12.5 billion. However, it plans to stop breaking out that figure starting next quarter, even as growth at Red Hat slowed to 10%. IBM also highlighted dealmaking moves, including HashiCorp and a planned $11 billion acquisition of Confluent. That Confluent deal could weigh on 2026 earnings by around $600 million. Reuters

IBM posted $19.7 billion in revenue for the fourth quarter, driven by a 14% increase in software and a 21% rise in infrastructure sales. Its IBM Z mainframe business soared 67%, fueled by demand for the newest platform.

IBM projects revenue growth above 5% for 2026 on a constant-currency basis, excluding FX fluctuations, along with roughly a $1 billion rise in free cash flow year-over-year. “We enter 2026 with momentum,” CEO Arvind Krishna said. Investing.com

IBM’s “generative AI book of business” blends software transaction revenue linked to generative AI with new SaaS annual contract value and consulting deals tied to specific offerings, the company explained. Since IBM stopped reporting that number separately in the first quarter, investors must rely more on segment data and management remarks to determine if AI demand is broadening or remains focused in select areas. IBM Newsroom

Red Hat remains the key driver. Growth in its hybrid-cloud segment eased, with CFO Jim Kavanaugh telling Reuters that the late-2025 U.S. government shutdown shaved “a couple points” off growth since federal agencies account for roughly 15% of hybrid cloud bookings. He also cautioned that the looming shutdown threat this week could trigger a “short-term disruption.” Investing.com

Some analysts emphasized the “defensive” angle. Stifel’s David Grossman called IBM’s enterprise software portfolio “more defensive than most vendors,” reaffirming a buy rating and a $325 price target, Barron’s reported.

IBM filed an 8-K on Wednesday, attaching its earnings release under Item 2.02.

Yet the upside scenario isn’t without its flaws. Should government-driven buying remain patchy or Red Hat fail to pick up speed again, investors might see the post-earnings jump as a flash in the pan. On top of that, integration hurdles and acquisition expenses could weigh on performance, while dropping the AI metric cuts transparency just when it’s most needed.

Thursday’s key question: Can IBM maintain the bulk of its premarket gains when regular hours kick in and volume rises? Investors should also mark their calendars — IBM’s $1.68 quarterly dividend will be paid on March 10 to shareholders recorded by Feb. 10.

Stock Market Today

  • Applied Materials 10-Year Investment Growth: $1000 to $20,312
    June 9, 2026, 10:25 AM EDT. A $1000 investment in Applied Materials (AMAT) made in June 2016 would be worth $20,312.42 as of June 2026, representing a 1,931.24% gain. Applied Materials, based in Santa Clara, California, supplies equipment for semiconductor device manufacturing, flat panel displays and solar PV products. Its business is divided into Semiconductor Systems, Applied Global Services, and Display segments. The company's tools support critical chipmaking processes, including deposition and implantation on silicon wafers. With over 33,000 systems installed globally, it competes mainly with equipment makers like KLAC and LRCX. This significant return highlights the potential rewards of long-term investment in semiconductor capital equipment providers.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Babcock share price today: BAB slips after fresh buyback filing, March year-end in focus
Previous Story

Babcock share price today: BAB slips after fresh buyback filing, March year-end in focus

Microsoft stock dives as AI spending bites; Nvidia steady, Meta jumps in split AI trade
Next Story

Microsoft stock dives as AI spending bites; Nvidia steady, Meta jumps in split AI trade

Go toTop